Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06452160 · ClinicalTrials.gov registry record · Phase 1
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
A Phase 1 study of Solid Tumor and Mesothelioma, sponsored by BridGene Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT06452160: Recruiting Phase 1 study of Solid Tumor and Mesothelioma, sponsored by BridGene Biosciences.
NCT06452160 is a Phase 1 study of Solid Tumor and Mesothelioma that is actively recruiting participants, run by BridGene Biosciences. The registered enrollment target is 103 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06452160, a Phase 1 study of Solid Tumor and Mesothelioma, is actively recruiting participants, sponsored by BridGene Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
Primary Outcome
AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. AE evaluation will be based on laboratory tests, vital signs, physical examination, and 12-lead electrocardiogram, etc.
Conditions Studied
Interventions
- DRUG BGC515
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2024-06-27 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT06452160 shows while recruiting
NCT06452160 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (53% lower).
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which BGC515 is the first listed.
NCT06452160 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06452160 about?
NCT06452160 is a clinical study titled "A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors". The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
What is the current status of trial NCT06452160?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2024-06-27. Estimated completion is 2027-12.
What conditions does trial NCT06452160 study?
This clinical trial studies the following conditions: Solid Tumor, Mesothelioma, Epithelioid Hemangioendothelioma (EHE).
What interventions are being tested in trial NCT06452160?
The interventions under investigation include: BGC515 (DRUG).
Who is sponsoring clinical trial NCT06452160?
This trial is sponsored by BridGene Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06452160 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06452160's enrollment target sits among peer trials
103 84th of 196 higher than 113 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI